AB 8939
Alternative Names: AB-8939Latest Information Update: 20 Jun 2025
At a glance
- Originator AB Science
- Class Antineoplastics; Imidazolidines; Oxazoles; Small molecules
- Mechanism of Action Aldehyde dehydrogenase inhibitors; Apoptosis stimulants; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia
Most Recent Events
- 16 Jun 2025 AB Science received patent for AB8939 in Europe, USA, Canada, China, South Korea, Japan, Hong Kong, Israel, Australia, Russia, Brazil, Mexico, India and South Africa
- 23 Apr 2025 AB 8939 receives Orphan Drug status for Acute myeloid leukaemia in European Union
- 17 Dec 2024 Pharmacodynamics data from the preclinical studies in Acute myeloid leukemia released by AB Science